The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret antigens that could form the backbone of off-the-shelf immunotherapies.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

In a grim update, Merck announced it is temporarily halting shipments of HPV vaccine Gardasil—its second-biggest product—to China. “Like many other companies, we’ve seen increased pressure ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.